Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Influenza A virus hemagglutinin H3 is a homotrimeric glycoprotein on the virus surface, consisting of HA1 and HA2 subunits linked by disulfide bonds, with a globular head domain for sialic acid receptor binding and a stem domain for membrane anchoring and pH-triggered fusion of viral and host endosomal membranes during entry.[2][3][4][5] The head (HA1) enables attachment to sialic acid on host cells like respiratory epithelium, while the stem (HA2) drives fusion at low pH (5.0-6.0), releasing viral genome.[2][3][4] H3 is one of 16 HA subtypes, key in H3N2 strains causing seasonal influenza and pandemics like 1968 Hong Kong flu; it evolves via mutations and N-glycosylation to evade immunity.[1][2][3] The receptor binding site shows variations for α2,6-linked sialic acid preference in human strains.[3] HA is the primary antigen, targeted by neutralizing antibodies, with conserved stem epitopes for broad protection efforts.[1][3][6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza A virus hemagglutinin H3 (HA (H3)).